4Bio Ventures — Full Portfolio
2 tracked investments · listed companies and verified rows first
Novaptix develops non-viral gene writing technology intended to support the development and scaling of gene therapies.
BiotechDeep TechMedical DevicesBerkeley, US
Kevin Holden(Executive Officer, Director, Promoter)
BoardAudrey Kozlov(Director)Daniel Dever(Director)
Board seatDmitry Kuzmin· per SEC Form D · $7.5M raise · filed Mar 2025
Restoring vision through optogenetics.
BiotechSan Francisco, US
Paul Bresge(Executive Officer, Director)Sean Ainsworth(Executive Officer, Director)
BoardTiba Aynechi(Director)inRaymond Camahort(Director)Hannah Chang(Director)
Board seatDmitry Kuzmin· per SEC Form D · $100M raise · filed May 2023
Co-investorsMRL Ventures FundNorwest Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.